– UK, Oxford – Circassia Pharmaceuticals plc (LSE: CIR), a specialty biopharmaceutical company focused on allergy, today announces the appointment of Lota S Zoth as a Non-Executive Director and member of the Remuneration Committee.  Ms Zoth will also join the Audit Committee as its Chair.  

Lota is an experienced Board member, and has significant financial experience gained in a number of global public companies.  Most recently she was CFO at MedImmune, and previously held senior positions at PSINet, Sodexho Marriott, PepsiCo and Ernst & Young.  

She is currently a Non-Executive Director, Compensation Committee Member and the Audit Committee Chair at Hyperion Therapeutics Inc and NewLink Genetics Corporation.  She is also a Non-Executive Director and the Audit Committee Chair at Orexigen Therapeutics Inc.  In addition, Lota is Chair of Aeras, a non-profit product development organisation focused on tuberculosis, and previously was a Non-Executive Director and the Audit Committee Chair at privately-held Ikaria Inc.  

Dr Francesco Granata, Circassia’s Chairman, said: “We are delighted to welcome Lota to Circassia.  With her impressive track record in the biopharmaceutical industry, and significant financial and Board experience, she will make a valuable contribution to the Company as we continue our transformation into a leading immunotherapy business.”

About Circassia

Circassia is a specialty biopharmaceutical company focused on the development and commercialisation of a range of allergy immunotherapy product candidates.  Established in 2006, the Company has used its proprietary ToleroMune® technology to develop a new class of therapies, the Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs), which have the potential to revolutionise allergy treatment.  

The Company’s portfolio of SPIREs is designed to treat a broad range of seasonal and perennial allergies.  The most advanced, Cat-SPIRE, targets cat allergy and is currently in phase III development.  Three other product candidates, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies.  

As Circassia continues to grow, the Company remains focused on its founding principle – a commitment to improving patients’ lives by controlling immune responses.

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.